Brian Toy is an Ophthalmology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1450 San Pablo St
4th Floor
Los Angeles, CA 900334500
Telephone
323-442-6335Provider last certified this registry record 25 Sept 2020.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ANI Pharmaceuticals, Inc.Program year20252 payments
- Bausch & Lomb Americas Inc.Program year20254 payments
- Regeneron Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
37.8%Corticosteroid20.2%Prednisolone Acetate100%Part D≥28 patientsCorticosteroids, plain11.4%Difluprednate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
24.4%Corticosteroid19.2%Prednisone100%Part D≥20 patientsAnticholinergic5.2%Atropine Sulfate100%Part D<11 patientsCancer & immunology
17.9%Folate Analog Metabolic Inhibitor7.8%Methotrexate100%Part D<11 patientsTNF inhibitor5.9%Humira(Cf) Pen100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Investigating the Development, Persistence, and Progression of Uveitis and Ocular Inflammation in the United States
University of Southern California
FY2025$164,013K23EY032985 - Health Disparities in the Development, Persistence, and Progression of Uveitis and Ocular Inflammation in the United States
University of Southern California
FY2024$164,013K23EY032985 - Health Disparities in the Development, Persistence, and Progression of Uveitis and Ocular Inflammation in the United States
University of Southern California
FY2023$164,013K23EY032985
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”